Search Results

You are looking at 41 - 50 of 595 items for :

  • "surveillance" x
Clear All
Full access

Kelly G. Paulson and Shailender Bhatia

,217 reported in 2001 to 2,246 reported in 2014. (B) Extent of disease at presentation. Information was available for 21,445 cases. Data from 2001–2014 Database: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski and Deborah A. Freedman-Cass

recurrent and metastatic disease, patient surveillance, and survivorship. These guidelines overlap considerably with the NCCN Guidelines for Colon Cancer, especially in the treatment of metastatic disease. Recommendations in these guidelines are classified

Full access

Philippe E. Spiess

inguinal disease. Thus, the NCCN Guidelines for managing non-palpable inguinal lymph nodes reflect these findings. For patients at low risk, surveillance is indicated, and DSNB is ranked as a category 2B option. For patients at high risk, inguinal lymph

Full access

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer and Miranda Hughes

Guidelines and debate among panel members about recent clinical trials. The topics include 1) intraperitoneal (IP) chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and

Full access

Martin C. Mahoney

. Available at : http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp . Accessed July 19, 2007 . 2. Surveillance, Epidemiology, and End Results (SEER) Program . DevCan database: SEER 17 Incidence and Mortality, 2000

Full access

Harry W. Herr

(A) immediate cystectomy versus (B) surveillance or delayed cystectomy. Abbreviations: DOC, death from other causes; DOD, dead of disease; DUC, death from unknown causes; RC, radical cystectomy; TUR, transurethral resection. nonrandomized

Full access

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory and Deborah A. Freedman-Cass

cancer has decreased by almost 35% from 1990 to 2007, 3 likely because of earlier diagnosis through screening and better treatment modalities. Surveillance for Early-Stage Disease While reviewing the guidelines during the annual panel meeting, a

Full access

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Lucille A. Leong, Edward Lin, Michael G. Martin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Deborah A. Freedman-Cass and Kristina M. Gregory

, management of recurrent and metastatic disease, patient surveillance, and survivorship. These guidelines overlap considerably with the NCCN Guidelines for Colon Cancer, especially in the treatment of metastatic disease (to view the most recent version of

Full access

Anthony J. Olszanski

therapy restricted to diseases for which specific mutations elicit a response,” he proposed. Immune Surveillance, Evasion, and Suppression The immunoediting hypothesis has 3 phases: the elimination phase, which consists of active immune

Full access

J. Sybil Biermann, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, James E. Butrynski, David Cheong, Warren Chow, William T. Curry, Deborah A. Frassica, Frank J. Frassica, Kenneth R. Hande, Francis J. Hornicek, Robin L. Jones, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Margaret von Mehren, Mary Anne Bergman and Hema Sundar

with demonstrated expertise in the management of these tumors. Long-term surveillance and follow-up are necessary when considering the risk of recurrence and comorbidities associated with chemotherapy and radiation therapy (RT). Life-long follow-up is